Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

This study plans to use 1.0×108PFU/day per cycle, intratumoral injection administration for 3 consecutive days, and 28 days as a cycle. Tumor imaging evaluation was performed every 8±1 weeks from the first dose of C1D1 until an event that met the criteria for treatment discontinuation occurred.

Trial Details

NCT ID
NCT06126510
Phase
PHASE2
Sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Subjects must give informed consent to this study before the trial and voluntarily sign a written informed consent form.
  • Age 18 to 75 years old (inclusive), gender is not limited.
  • Patients with advanced bone and soft tissue sarcoma confirmed by histopathological or cytology, who are unresectable by surgery and have failed at …
  • According to RECIST 1.1, it is determined that at least one CT examination shows measurable and meets the volume requirement for the first injectio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →